Synopsis
Synopsis
0
JDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. By 1023
2. By-1023
3. By1023
4. Pantoprazole
5. Protonix
6. Sk And F 96022
7. Sk And F-96022
8. Sk And F96022
9. Skf 96022
10. Skf-96022
11. Skf96022
1. 138786-67-1
2. Pantoloc
3. Protonix
4. Pantecta
5. Zurcal
6. Pantoprazole Sodium Salt
7. Skf96022 Sodium
8. By-1023 Sodium
9. Chebi:50270
10. Sodium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
11. Pantozol Control
12. 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl) Sulfinyl)-1h-benzimidazole Sodium
13. Dsstox_cid_24215
14. Dsstox_rid_80123
15. Dsstox_gsid_44215
16. Sodium 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
17. Sodium 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
18. Cas-138786-67-1
19. Anagastra
20. Inipomp
21. Pantorc
22. Peptazol
23. Ulcotenal
24. Citrel
25. Apton
26. Rifun
27. Pantoprazole Sodium;
28. By1023 (sodium)
29. Pantoprazole Sodium,(s)
30. Skf96022 (sodium)
31. Schembl3543
32. Mls001424073
33. Pantoprazole Sodium Monohydrate
34. Chembl1200408
35. Dtxsid7044215
36. Dz-2352a
37. Hms2051l19
38. Hms3393l19
39. Hms3715d12
40. Act02633
41. Tox21_112996
42. Tox21_302362
43. Mfcd01658543
44. S4538
45. Akos015994677
46. Ccg-100980
47. Ks-1093
48. Nc00230
49. S86p671
50. Sb17369
51. By-1023/sk&f-96022
52. Ncgc00255835-01
53. Smr000469592
54. Ft-0602602
55. Ft-0673508
56. A807440
57. B-8610-23/sk&f-96022-z
58. J-516336
59. B-8510-29
60. Q27122012
61. Sodium 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl] Benzimidazol-1-ide
62. 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole, Sodium Salt
63. 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]benzimidazol-1-ide; Sodium;pantoprazole Sodium
64. Sodium 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
65. Sodium 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}benzimidazol-1-ide
1. Pantozol
2. S-pantoprazole
3. Pantoprazole
Molecular Weight | 405.4 g/mol |
---|---|
Molecular Formula | C16H14F2N3NaO4S |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 7 |
Exact Mass | 405.05707772 g/mol |
Monoisotopic Mass | 405.05707772 g/mol |
Topological Polar Surface Area | 90.8 Ų |
Heavy Atom Count | 27 |
Formal Charge | 0 |
Complexity | 497 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Pantoprazole sodium |
Drug Label | The active ingredient in pantoprazole sodium delayed-release tablets USP is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid... |
Active Ingredient | Pantoprazole sodium |
Dosage Form | Injectable; Tablet, delayed release |
Route | injection; Iv (infusion); Oral |
Strength | eq 20mg base; eq 40mg base/vial; eq 40mg base; 40mg |
Market Status | Tentative Approval; Prescription |
Company | Wockhardt; Mylan Pharms; Hetero Labs Ltd V; Teva Parenteral; Teva; Apotex; Aurobindo Pharma; Torrent Pharms; Sun Pharma Global; Perrigo R And D; Actavis Elizabeth; Macleods Pharms; Jubilant Generics; Kudco Ireland; Ranbaxy Labs; Dr Reddys Labs; Akorn |
2 of 4 | |
---|---|
Drug Name | Protonix iv |
Active Ingredient | Pantoprazole sodium |
Dosage Form | Injectable |
Route | Iv (infusion) |
Strength | eq 40mg base/vial |
Market Status | Prescription |
Company | Wyeth Pharms |
3 of 4 | |
---|---|
Drug Name | Pantoprazole sodium |
Drug Label | The active ingredient in pantoprazole sodium delayed-release tablets USP is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl] sulfinyl]-1H-benzimidazole sesquihydrate, a compound that inhibits gastric acid... |
Active Ingredient | Pantoprazole sodium |
Dosage Form | Injectable; Tablet, delayed release |
Route | injection; Iv (infusion); Oral |
Strength | eq 20mg base; eq 40mg base/vial; eq 40mg base; 40mg |
Market Status | Tentative Approval; Prescription |
Company | Wockhardt; Mylan Pharms; Hetero Labs Ltd V; Teva Parenteral; Teva; Apotex; Aurobindo Pharma; Torrent Pharms; Sun Pharma Global; Perrigo R And D; Actavis Elizabeth; Macleods Pharms; Jubilant Generics; Kudco Ireland; Ranbaxy Labs; Dr Reddys Labs; Akorn |
4 of 4 | |
---|---|
Drug Name | Protonix iv |
Active Ingredient | Pantoprazole sodium |
Dosage Form | Injectable |
Route | Iv (infusion) |
Strength | eq 40mg base/vial |
Market Status | Prescription |
Company | Wyeth Pharms |
Short-term treatment of reflux symptoms (e. g. heartburn, acid regurgitation) in adults.
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
A02BC02
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36375
Submission : 2021-12-28
Status : Active
Type : II
Certificate Number : R0-CEP 2021-427 - Rev 00
Issue Date : 2022-11-02
Type : Chemical
Substance Number : 2296
Status : Valid
Date of Issue : 2025-02-27
Valid Till : 2028-03-17
Written Confirmation Number : WC-0004
Address of the Firm :
NDC Package Code : 49716-334
Start Marketing Date : 2023-10-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : RU |
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Certificate Number : CEP 2023-421 - Rev 00
Issue Date : 2024-07-16
Type : Chemical
Substance Number : 2296
Status : Valid
Date of Issue : 2024-08-16
Valid Till : 2027-02-26
Written Confirmation Number : WC-0494
Address of the Firm :
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35577
Submission : 2021-03-29
Status : Active
Type : II
Certificate Number : CEP 2021-168 - Rev 01
Issue Date : 2024-06-21
Type : Chemical
Substance Number : 2296
Status : Valid
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-001
Start Marketing Date : 2018-01-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-02-07
Pay. Date : 2019-02-01
DMF Number : 17103
Submission : 2004-01-20
Status : Active
Type : II
Certificate Number : R1-CEP 2010-319 - Rev 01
Issue Date : 2017-03-28
Type : Chemical
Substance Number : 2296
Status : Valid
Date of Issue : 2022-05-26
Valid Till : 2025-06-25
Written Confirmation Number : WC-0035
Address of the Firm :
NDC Package Code : 55111-051
Start Marketing Date : 2004-01-20
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-03-22
Pay. Date : 2019-03-11
DMF Number : 18779
Submission : 2005-09-15
Status : Active
Type : II
Certificate Number : R1-CEP 2009-323 - Rev 02
Issue Date : 2020-01-31
Type : Chemical
Substance Number : 2296
Status : Valid
NDC Package Code : 68069-0005
Start Marketing Date : 2010-07-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
About the Company : With a history spanning over three decades, IOL Chemicals and Pharmaceuticals Limited is an innovation-driven company that specializes in bulk drugs, intermediates and specialty ch...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for critical and high-g...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...
About the Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It has been fostering g...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Pantoprazole Sodium Sesquihydrate
About the Company : Gonane Pharma, is a contract pharmaceutical company located in Gujarat, India, specializing in the manufacturing and marketing of Corticosteroids, Hormones, Antivirals, and Oncolog...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 ...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
https://www.pharmacompass.com/radio-compass-blog/fda-s-first-generic-approvals-slump-21-in-2024-novartis-top-seller-entresto-cancer-blockbuster-tasigna-lead-2024-patent-cliff
Global Sales Information
Market Place
Reply
22 May 2025
Reply
12 Apr 2025
Reply
12 Mar 2025
Reply
27 Dec 2024
Reply
24 Dec 2024
Reply
07 Dec 2024
Reply
07 Nov 2024
Reply
30 Sep 2024
Reply
24 Sep 2024
Reply
16 Sep 2024
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
84
PharmaCompass offers a list of Pantoprazole Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Pantoprazole Sodium manufacturer or Pantoprazole Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Pantoprazole Sodium manufacturer or Pantoprazole Sodium supplier.
PharmaCompass also assists you with knowing the Pantoprazole Sodium API Price utilized in the formulation of products. Pantoprazole Sodium API Price is not always fixed or binding as the Pantoprazole Sodium Price is obtained through a variety of data sources. The Pantoprazole Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Peptazol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Peptazol, including repackagers and relabelers. The FDA regulates Peptazol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Peptazol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Peptazol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Peptazol supplier is an individual or a company that provides Peptazol active pharmaceutical ingredient (API) or Peptazol finished formulations upon request. The Peptazol suppliers may include Peptazol API manufacturers, exporters, distributors and traders.
click here to find a list of Peptazol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Peptazol DMF (Drug Master File) is a document detailing the whole manufacturing process of Peptazol active pharmaceutical ingredient (API) in detail. Different forms of Peptazol DMFs exist exist since differing nations have different regulations, such as Peptazol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Peptazol DMF submitted to regulatory agencies in the US is known as a USDMF. Peptazol USDMF includes data on Peptazol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Peptazol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Peptazol suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Peptazol Drug Master File in Korea (Peptazol KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Peptazol. The MFDS reviews the Peptazol KDMF as part of the drug registration process and uses the information provided in the Peptazol KDMF to evaluate the safety and efficacy of the drug.
After submitting a Peptazol KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Peptazol API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Peptazol suppliers with KDMF on PharmaCompass.
A Peptazol CEP of the European Pharmacopoeia monograph is often referred to as a Peptazol Certificate of Suitability (COS). The purpose of a Peptazol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Peptazol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Peptazol to their clients by showing that a Peptazol CEP has been issued for it. The manufacturer submits a Peptazol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Peptazol CEP holder for the record. Additionally, the data presented in the Peptazol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Peptazol DMF.
A Peptazol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Peptazol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Peptazol suppliers with CEP (COS) on PharmaCompass.
A Peptazol written confirmation (Peptazol WC) is an official document issued by a regulatory agency to a Peptazol manufacturer, verifying that the manufacturing facility of a Peptazol active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Peptazol APIs or Peptazol finished pharmaceutical products to another nation, regulatory agencies frequently require a Peptazol WC (written confirmation) as part of the regulatory process.
click here to find a list of Peptazol suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Peptazol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Peptazol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Peptazol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Peptazol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Peptazol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Peptazol suppliers with NDC on PharmaCompass.
Peptazol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Peptazol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Peptazol GMP manufacturer or Peptazol GMP API supplier for your needs.
A Peptazol CoA (Certificate of Analysis) is a formal document that attests to Peptazol's compliance with Peptazol specifications and serves as a tool for batch-level quality control.
Peptazol CoA mostly includes findings from lab analyses of a specific batch. For each Peptazol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Peptazol may be tested according to a variety of international standards, such as European Pharmacopoeia (Peptazol EP), Peptazol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Peptazol USP).